Ustekinumab Biosimilar is a monoclonal antibody commercialized by Sandoz Group, with a leading Pre-Registration program in Plaque Psoriasis (Psoriasis Vulgaris). According to Globaldata, it is involved in 2 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of Ustekinumab Biosimilar’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Ustekinumab Biosimilar is expected to reach an annual total of $378 mn by 2039 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Ustekinumab Biosimilar Overview

Ustekinumab biosimilar (SB17) is under development for the treatment of autoimmune disorders including plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. It is administered through subcutaneous route. The drug candidate is monoclonal antibody that acts by targeting interleukin 12 subunit beta and interleukin 23 subunit alpha. 

Sandoz Group Overview

Sandoz Group develops, manufactures and distributes generics and biosimilar medical products used for the treatment of various life threatening diseases. The company is headquartered in Zug City, Zug, Switzerland.

The company reported revenues of (US Dollars) US$9,306 million for the fiscal year ended December 2022 (FY2022), a decrease of 3.8% over FY2021. In FY2022, the company’s operating margin was 13.3%, compared to an operating margin of 14.4% in FY2021. In FY2022, the company recorded a net margin of 9.1%, compared to a net margin of 9.4% in FY2021.

For a complete picture of Ustekinumab Biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.